The purpose was to explore the contribution of the presenting demographic, clinical and laboratory characteristics to the survival status at discharge and duration of admission. The study used secondary data of the Burkitts Lymphoma (BL) patients who were admitted at St. Mary’s Hospital Lacor between the period 2003 and 2009. Regressive methods were developed to establish the factors explaining the dependent variables. Whereas majority of the admissions were males (60%), the proportion of females diagnosed with the cancer progressively increased more than that of males over years. Regardless of any other anatomic site involved; 74 percent of the patients had abdominal tumors, 49 percent had tumors in the face and 23 percent had tumors in the CNS. Females were more likely to have abdominal tumor involvement than males. On the other hand, males were twice more likely to have facial or CNS tumor involvement than the females. Over 80 percent of the patients were staged C or D suggesting delays in seeking for treatment. Patients with adnominal or CNS tumor involvement were more likely to be staged C or D. Seven percent died within the average admission period of 96 days. All deaths were observed among stages C and D patients. The duration of admission between the discharged dead and alive was significantly different. Stage C and D patients tended to have longer duration of admission. Further, older patients tended to have a longer duration of admission than the younger ones. Other variables such as sex, and site tumor involvement did not have a significant effect on the duration of admission. The duration of admission and survival status tended to influence each other. Though marginal, age at admission had a significant role to play in explaining the length of admission. The deaths before admission were observed among stage C and D patients, of which over 80% of the patients were staged. This calls in a community-level follow-up study to assess their survival. The above findings suggest an accelerated risk to death among the discharged stage C and D patients.
Published in | American Journal of Health Research (Volume 2, Issue 1) |
DOI | 10.11648/j.ajhr.20140201.12 |
Page(s) | 9-14 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2014. Published by Science Publishing Group |
Burkitts Lymphoma, Survival Status, Length of Admission, Determining Factors
[1] | O. H. Iversen, U. Iversen, J. L. Ziegler, and A. Z. Bluming, "Cell kinetics in Burkitt lymphoma," European Journal of Cancer (1965), vol. 10, pp. 155-163, 1974. |
[2] | I. Magrath, E. Steliarova-Foucher, S. Epelman, R. C. Ribeiro, M. Harif, C.-K. Li, R. Kebudi, S. D. Macfarlane, and S. C. Howard, "Paediatric cancer in low-income and middle-income countries," The lancet oncology, 2012. |
[3] | S. M. Mbulaiteye, "Burkitt Lymphoma: beyond discoveries," Infectious agents and cancer, vol. 8, pp. 1-4, 2013. |
[4] | R. R. Miles, S. Arnold, and M. S. Cairo, "Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia," British journal of haematology, vol. 156, pp. 730-743, 2013. |
[5] | C. L. M. Olweny, E. Katongole Mbidde, D. Otim, S. K. Lwanga, I. T. Magrath, and J. L. Ziegler, "Long-term experience with burkitt's lymphoma in uganda," International journal of cancer, vol. 26, pp. 261-266, 1980. |
[6] | W. I. Aderele and A. U. Antia, "Burkitt's lymphoma in children at Ibadan-A review of 133 cases," Nig J Paediatr, vol. 6, pp. 1-14, 1979. |
[7] | J. Orem, E. K. Mbidde, B. Lambert, S. de Sanjose, and E. Weiderpass, "Burkitt's lymphoma in Africa, a review of the epidemiology and etiology," African health sciences, vol. 7, 2007. |
[8] | R. H. Morrow, M. C. Pike, and A. Kisuule, "Survival of Burkitt's lymphoma patients in Mulago Hospital, Uganda," British medical journal, vol. 4, p. 323, 1967. |
[9] | B. M. Kagu, O. O. Adeodu, N. O. Akinola, I. A. Adediran, and L. Salawu, "Determinants of survival in Nigerians with Burkitt's lymphoma," African journal of medicine and medical sciences, vol. 33, p. 195, 2004. |
[10] | C. K. O. Williams, A. O. Folami, and O. Seriki, "Patterns of treatment failure in Burkitt's lymphoma," European Journal of Cancer and Clinical Oncology, vol. 19, pp. 741-46, 1983. |
[11] | M. S. R. Hutt and D. Burkitt, "Geographical distribution of cancer in East Africa: a new clinicopathological approach," British medical journal, vol. 2, p. 719, 1965. |
[12] | S. Baik, M. Mbaziira, M. Williams, M. D. Ogwang, T. Kinyera, B. Emmanuel, J. L. Ziegler, S. J. Reynolds, and S. M. Mbulaiteye, "A case-control study of Burkitt lymphoma in East Africa: are local health facilities an appropriate source of representative controls?," Infectious agents and cancer, vol. 7, pp. 1-7, 2012. |
[13] | M. S. McGrath, B. Herndier, and B. Shiramizu, "Diagnosis and treatment of cancer having clonal macrophage involvement," Google Patents, 1998. |
[14] | D. P. Burkitt and S. K. Kyalwazi, "Spontaneous remission of African lymphoma," British journal of cancer, vol. 21, p. 14, 1967. |
APA Style
Mbazira Mike, Wesonga Ronald, Nabugoomu Fabian. (2014). Survival Factors of Burkitts Lymphoma Patients at Discharge: The Case of St. Mary’s Hospital Lacor in Northern Uganda. American Journal of Health Research, 2(1), 9-14. https://doi.org/10.11648/j.ajhr.20140201.12
ACS Style
Mbazira Mike; Wesonga Ronald; Nabugoomu Fabian. Survival Factors of Burkitts Lymphoma Patients at Discharge: The Case of St. Mary’s Hospital Lacor in Northern Uganda. Am. J. Health Res. 2014, 2(1), 9-14. doi: 10.11648/j.ajhr.20140201.12
AMA Style
Mbazira Mike, Wesonga Ronald, Nabugoomu Fabian. Survival Factors of Burkitts Lymphoma Patients at Discharge: The Case of St. Mary’s Hospital Lacor in Northern Uganda. Am J Health Res. 2014;2(1):9-14. doi: 10.11648/j.ajhr.20140201.12
@article{10.11648/j.ajhr.20140201.12, author = {Mbazira Mike and Wesonga Ronald and Nabugoomu Fabian}, title = {Survival Factors of Burkitts Lymphoma Patients at Discharge: The Case of St. Mary’s Hospital Lacor in Northern Uganda}, journal = {American Journal of Health Research}, volume = {2}, number = {1}, pages = {9-14}, doi = {10.11648/j.ajhr.20140201.12}, url = {https://doi.org/10.11648/j.ajhr.20140201.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20140201.12}, abstract = {The purpose was to explore the contribution of the presenting demographic, clinical and laboratory characteristics to the survival status at discharge and duration of admission. The study used secondary data of the Burkitts Lymphoma (BL) patients who were admitted at St. Mary’s Hospital Lacor between the period 2003 and 2009. Regressive methods were developed to establish the factors explaining the dependent variables. Whereas majority of the admissions were males (60%), the proportion of females diagnosed with the cancer progressively increased more than that of males over years. Regardless of any other anatomic site involved; 74 percent of the patients had abdominal tumors, 49 percent had tumors in the face and 23 percent had tumors in the CNS. Females were more likely to have abdominal tumor involvement than males. On the other hand, males were twice more likely to have facial or CNS tumor involvement than the females. Over 80 percent of the patients were staged C or D suggesting delays in seeking for treatment. Patients with adnominal or CNS tumor involvement were more likely to be staged C or D. Seven percent died within the average admission period of 96 days. All deaths were observed among stages C and D patients. The duration of admission between the discharged dead and alive was significantly different. Stage C and D patients tended to have longer duration of admission. Further, older patients tended to have a longer duration of admission than the younger ones. Other variables such as sex, and site tumor involvement did not have a significant effect on the duration of admission. The duration of admission and survival status tended to influence each other. Though marginal, age at admission had a significant role to play in explaining the length of admission. The deaths before admission were observed among stage C and D patients, of which over 80% of the patients were staged. This calls in a community-level follow-up study to assess their survival. The above findings suggest an accelerated risk to death among the discharged stage C and D patients.}, year = {2014} }
TY - JOUR T1 - Survival Factors of Burkitts Lymphoma Patients at Discharge: The Case of St. Mary’s Hospital Lacor in Northern Uganda AU - Mbazira Mike AU - Wesonga Ronald AU - Nabugoomu Fabian Y1 - 2014/01/10 PY - 2014 N1 - https://doi.org/10.11648/j.ajhr.20140201.12 DO - 10.11648/j.ajhr.20140201.12 T2 - American Journal of Health Research JF - American Journal of Health Research JO - American Journal of Health Research SP - 9 EP - 14 PB - Science Publishing Group SN - 2330-8796 UR - https://doi.org/10.11648/j.ajhr.20140201.12 AB - The purpose was to explore the contribution of the presenting demographic, clinical and laboratory characteristics to the survival status at discharge and duration of admission. The study used secondary data of the Burkitts Lymphoma (BL) patients who were admitted at St. Mary’s Hospital Lacor between the period 2003 and 2009. Regressive methods were developed to establish the factors explaining the dependent variables. Whereas majority of the admissions were males (60%), the proportion of females diagnosed with the cancer progressively increased more than that of males over years. Regardless of any other anatomic site involved; 74 percent of the patients had abdominal tumors, 49 percent had tumors in the face and 23 percent had tumors in the CNS. Females were more likely to have abdominal tumor involvement than males. On the other hand, males were twice more likely to have facial or CNS tumor involvement than the females. Over 80 percent of the patients were staged C or D suggesting delays in seeking for treatment. Patients with adnominal or CNS tumor involvement were more likely to be staged C or D. Seven percent died within the average admission period of 96 days. All deaths were observed among stages C and D patients. The duration of admission between the discharged dead and alive was significantly different. Stage C and D patients tended to have longer duration of admission. Further, older patients tended to have a longer duration of admission than the younger ones. Other variables such as sex, and site tumor involvement did not have a significant effect on the duration of admission. The duration of admission and survival status tended to influence each other. Though marginal, age at admission had a significant role to play in explaining the length of admission. The deaths before admission were observed among stage C and D patients, of which over 80% of the patients were staged. This calls in a community-level follow-up study to assess their survival. The above findings suggest an accelerated risk to death among the discharged stage C and D patients. VL - 2 IS - 1 ER -